Aquestive Therapeutics reports positive study results for Anaphylm sublingual film, paving the way for a Q3 FDA resubmission.
Aquestive Therapeutics Inc.
(NASDAQ:AQST) announced positive findings from human factors and pharmacokinetic validation studies for its Anaphylm (dibutepinephrine) sublingual film.
The update strengthens the company's position ahead of an intended New Drug Application resubmission to the U.S.
Food and Drug Administration (FDA) for Type 1 allergic reactions, including anaphylaxis. • Aquestive Therapeutics stock is showing exceptional strength.
Why is AQST stock up today?
New Anaphylm sublingual epinephrine data address FDA’s concerns
Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist ASC35
Multiple human factors improved following revision of the packaging design and instructions for use on Anaphylm sublingual…
AbbVie has received approval from the EC for Aquipta, an oral CGRP receptor antagonist, for the acute treatment of migraine in…
ADDF Statement: FDA Approval of Subcutaneous Starting Dose for Leqembi Advances Alzheimer's Care Toward Combination Therapy Future
LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's…
uniQure stock surged after the FDA said three-year AMT-130 data could support accelerated approval for Huntington's disease…
Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide…
